Trefoil Therapeutics is a clinical-stage biotechnology company driven by the mission to restore sight to the millions of people who live with corneal diseases through the advancement of regenerative therapies. Founded and led by scientists with deep experience in the ophthalmology field, Trefoil is advancing an approach that leverages novel technology to treat a number of different corneal diseases. The company’s lead investigational medicine – TTHX1114 – has the potential to be first-in-class and is being studied for the treatment of corneal endothelial dystrophies and conditions via intracameral injection.